Compare IBTA & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBTA | ODTX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 750.2M | 875.1M |
| IPO Year | 2024 | 2026 |
| Metric | IBTA | ODTX |
|---|---|---|
| Price | $26.25 | $18.66 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $28.50 | N/A |
| AVG Volume (30 Days) | 150.6K | ★ 291.8K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $342,389,000.00 | N/A |
| Revenue This Year | $2.02 | N/A |
| Revenue Next Year | $8.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.10 | $15.10 |
| 52 Week High | $40.49 | $20.00 |
| Indicator | IBTA | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.67 | 49.94 |
| Support Level | $20.97 | $17.45 |
| Resistance Level | $35.47 | $19.59 |
| Average True Range (ATR) | 1.98 | 1.41 |
| MACD | -0.65 | 0.18 |
| Stochastic Oscillator | 14.82 | 78.34 |
Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.